Literature DB >> 17383120

Phosphatidylinositol-3 kinase/Akt/p70S6K/AP-1 signaling pathway mediated benzo(a)pyrene-induced cell cycle alternation via cell cycle regulatory proteins in human embryo lung fibroblasts.

Ai Gao1, Bingci Liu, Xianglin Shi, Xiaowei Jia, Meng Ye, Shi Jiao, Baorong You, Chuanshu Huang.   

Abstract

Benzo(a)pyrene (B(a)P), a potent environmental procarcinogen, has been shown to cause cell cycle alternation. However, the mechanisms involved in this effect are not well understood yet. Our current results demonstrated that B(a)P exposure led to cell proliferation and a 33.5% increase in S phase cells as well as a 26.8% decrease in G1 phase cells in human embryo lung fibroblasts (HELFs). Those cell cycle alternations were accompanied with transactivation of activator protein-1 (AP-1) and phosphorylation of Akt and p70(S6K). These changes were blocked by overexpression of dominant negative mutants of phosphatidylinositol-3 kinase (Deltap85) or Akt (DN-Akt), respectively. Moreover, pretreatment of cells with rapamycin, a specific p70(S6K) inhibitor, inhibited B(a)P-induced AP-1 activation, cell cycle alteration and phosphorylation of p70(S6K), but had no effect on Akt phosphorylation. Our results, therefore, suggest that phosphatidylinositol-3 kinase (PI-3K)/Akt/p70(S6K)/AP-1 pathway participates in B(a)P-induced cell cycle alternations. Furthermore, we explored the effect of this pathway on cell cycle regulatory proteins. B(a)P markedly increases in the expression of cyclin D1 and E2F1 and phosphorylation of retinoblastoma protein (Rb). In addition, we found that inactivation of PI-3K, Akt or p70(S6K) could eliminate those effects on cell cycle regulatory proteins. Collectively, PI-3K/Akt/p70(S6K)/AP-1 pathway mediated B(a)P-induced alternation of cell cycle through regulation of cell cycle regulatory proteins such as cyclin D1, E2F1, and Rb in HELFs.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17383120     DOI: 10.1016/j.toxlet.2007.02.008

Source DB:  PubMed          Journal:  Toxicol Lett        ISSN: 0378-4274            Impact factor:   4.372


  6 in total

1.  Phosphatase specificity and pathway insulation in signaling networks.

Authors:  Michael A Rowland; Brian Harrison; Eric J Deeds
Journal:  Biophys J       Date:  2015-02-17       Impact factor: 4.033

2.  Benzo(a)pyrene-caused increased G1-S transition requires the activation of c-Jun through p53-dependent PI-3K/Akt/ERK pathway in human embryo lung fibroblasts.

Authors:  Shi Jiao; Bingci Liu; Ai Gao; Meng Ye; Xiaowei Jia; Fengmei Zhang; Haifeng Liu; Xianglin Shi; Chuanshu Huang
Journal:  Toxicol Lett       Date:  2008-03-27       Impact factor: 4.372

3.  mot-2-Mediated cross talk between nuclear factor-B and p53 is involved in arsenite-induced tumorigenesis of human embryo lung fibroblast cells.

Authors:  Yuan Li; Yuan Xu; Min Ling; Ye Yang; Shoulin Wang; Zhong Li; Jianwei Zhou; Xinru Wang; Qizhan Liu
Journal:  Environ Health Perspect       Date:  2010-03-03       Impact factor: 9.031

4.  Hepatitis B spliced protein (HBSP) promotes the carcinogenic effects of benzo [alpha] pyrene by interacting with microsomal epoxide hydrolase and enhancing its hydrolysis activity.

Authors:  Jin-Yan Chen; Wan-Nan Chen; Bo-Yan Jiao; Wan-Song Lin; Yun-Li Wu; Ling-Ling Liu; Xu Lin
Journal:  BMC Cancer       Date:  2014-04-23       Impact factor: 4.430

5.  Feedback regulations of miR-21 and MAPKs via Pdcd4 and Spry1 are involved in arsenite-induced cell malignant transformation.

Authors:  Lu Shen; Min Ling; Yuan Li; Yuan Xu; Yun Zhou; Jing Ye; Ying Pang; Yue Zhao; Rongrong Jiang; Jianping Zhang; Qizhan Liu
Journal:  PLoS One       Date:  2013-03-01       Impact factor: 3.240

6.  Utilizing proteomic approach to identify nuclear translocation related serine kinase phosphorylation site of GNMT as downstream effector for benzo[a]pyrene.

Authors:  Ming-Hui Yang; Chen-Chung Liao; Jung-Hsien Hung; Xiu-Ting Lai; Chia-Hung Yen; Yi-Ming Arthur Chen
Journal:  J Food Drug Anal       Date:  2019-01-08       Impact factor: 6.157

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.